



CIN # L51900GJ1980PLC065554



**SEPL/SE/FEB/25-26**

**12<sup>th</sup> February 2026**

**The General Manager,  
Corporate Relations/Listing  
Department  
BSE Limited**  
Floor 25, P.J. Towers,  
Dalal Street,  
Mumbai – 400 001  
**Scrip Code: 501423**

**The Manager,  
Listing Department  
National Stock Exchange of India Limited**  
Exchange Plaza, Plot No. C/1, G Block,  
Bandra – Kurla Complex,  
Bandra (E),  
Mumbai – 400 051  
**Scrip Code: SHAILY**

**Sub: Q3FY26 - Result Presentation**

**Ref: Regulation 30 of the SEBI Listing Regulations, 2015**

Dear Sir,

In continuation to our letter dated 05<sup>th</sup> February 2026, regarding intimation of Earnings Call of the Company scheduled on Friday, 13<sup>th</sup> February 2026 at 04:00 p.m., to discuss the operational & financial performance of the Company for the quarter and nine months ended on 31<sup>st</sup> December 2025, kindly find enclosed herewith Q3FY26 Result Presentation of the Company.

A copy of the same is also available on our website <https://shaily.com/investors/compliances-policies/earnings-call>

Thanking You.

Yours truly,  
**For Shaily Engineering Plastics Limited**

**Harish Punwani  
Company Secretary & Compliance Officer  
M. No. A 50950**

*Encl: a/a*



This presentation and the accompanying slides (the "Presentation"), which have been prepared by **Shaily Engineering Plastics Limited** (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company's ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections.



**Key Performance Highlights**

## Appointment of COO (Healthcare)

**Mr. Joe Kam** is to be appointed as the **Chief Operating Officer (Healthcare)** of Shaily Engineering Plastics, effective 1<sup>st</sup> March 2026

- Over 2 decades of international experience in manufacturing and operations across highly-regulated and process-driven industries
- Prior to joining Shaily, he held senior leadership positions at SHL Medical, most recently as Senior Manufacturing Director responsible for 9 manufacturing sites in Taiwan and USA and at Flextronics as Plant Manager and Senior Project Manager
- Holds an Executive MBA from The Chinese University of Hong Kong and advanced academic qualifications in Automation Systems and Engineering Management

At Shaily, Joe will lead the global healthcare operations platform with a clear focus on driving operational excellence, strengthening quality and compliance frameworks, accelerating automation and building high-performing teams to support the company's next phase of growth.

## Healthcare

- 2 new customers were onboarded in the fast-growing GLP-1 segment
- Signed 2 new contracts with global companies for the manufacture and supply of pen injectors

## Industrial

- Supply of Power Tool components from a new customer
- Components for LED lighting applications

## Consumer

- A new product mandate from an existing home furnishing customer

## Setting up of a Facility in Abu Dhabi for manufacturing Medical Devices

- **Investment:** AED 130–150 million
- **Capacity:** ~75 million pen injectors p.a.
- **Operational timeline:** Q4 FY28



- Strategic expansion to support **global GLP-1 opportunity**
- Expands global manufacturing footprint



- Building **scalable capacity** in a fast-growing drug-delivery segment
- Enhances **proximity to international customers**




In discussions with Abu Dhabi Investment Office (ADIO) for **potential financial support**


# Key Financial Highlights – Q3 & 9M FY26 (Consolidated\*)




## Revenues




## Gross Profit Margin




## EBITDA




## EBITDA Margins



## Profit After Tax




## Cash PAT<sup>#</sup>



# Segment Wise Revenue Breakup


## Revenue (Consumer)




## Revenue (Healthcare)




## Revenue (Industrial)




## TOTAL REVENUE



## Revenue (Consumer)




## Revenue (Healthcare)



## Revenue (Industrial)




## TOTAL REVENUE




Improved traction in the healthcare segment has been the key driver for the overall growth of the business

# Key Financial Highlights – Q3 & 9M FY26 (Standalone)


## Revenues




## Gross Profit Margin




## EBITDA




## EBITDA Margins



## Profit After Tax



## Cash PAT<sup>#</sup>





(Rs. Cr.)



<sup>#</sup>Cash PAT includes PAT & Depreciation

# Operational Trends

## Machine Utilization Across Plants (%)



## Volume of Polymers Processed (MT)





## Revenue Analysis – Domestic vs. Exports

Q3 FY25

vs.



Q3 FY26



9M FY25

vs.

9M FY26







# Efficient Use of Capital

**RoCE**

**RoE**

**Fixed Asset Turnover**

**Total Debt / Equity**



# Profit & Loss Statement



Consolidated							Standalone					
Particulars (Rs. Crs.)	Q3 FY26	Q3 FY25	YoY %	9M FY26	9M FY25	YoY %	Q3 FY26	Q3 FY25	YoY %	9M FY26	9M FY25	YoY %
<b>Revenue</b>	<b>250.5</b>	<b>197.6</b>	<b>27%</b>	<b>753.8</b>	<b>569.0</b>	<b>32%</b>	<b>236.4</b>	<b>186.3</b>	<b>27%</b>	<b>697.1</b>	<b>534.8</b>	<b>30%</b>
Raw Material	104.1	103.7		329.1	310.6		104.0	103.7		320.7	310.6	
Employee Expenses	28.2	19.6		79.4	57.2		22.9	17.6		64.0	53.1	
Other Expenses*	51.4	28.4		131.0	79.6		45.6	27.0		120.2	75.5	
Other Income	-0.3	0.4		4.1	2.2		-0.1	0.4		4.2	2.9	
<b>EBITDA</b>	<b>66.4</b>	<b>46.3</b>	<b>43%</b>	<b>218.4</b>	<b>123.8</b>	<b>76%</b>	<b>63.8</b>	<b>38.5</b>	<b>66%</b>	<b>196.5</b>	<b>98.6</b>	<b>99%</b>
<b>EBITDA Margin</b>	<b>26.5%</b>	<b>23.4%</b>	<b>310 bps</b>	<b>29.0%</b>	<b>21.7%</b>	<b>720 bps</b>	<b>27.0%</b>	<b>20.6%</b>	<b>630 bps</b>	<b>28.2%</b>	<b>18.4%</b>	<b>980 bps</b>
Depreciation	12.5	10.7		36.0	31.1		11.7	9.9		33.4	29.1	
Finance Cost	4.4	4.1		12.2	13.0		4.4	4.1		12.2	13.0	
<b>PBT</b>	<b>49.5</b>	<b>31.5</b>	<b>57%</b>	<b>170.3</b>	<b>79.7</b>	<b>114%</b>	<b>47.8</b>	<b>24.4</b>	<b>95%</b>	<b>150.9</b>	<b>56.5</b>	<b>167%</b>
<b>PBT Margin</b>	<b>19.8%</b>	<b>15.9%</b>		<b>22.6%</b>	<b>14.0%</b>		<b>20.2%</b>	<b>13.1%</b>		<b>21.6%</b>	<b>10.6%</b>	
Tax	12.1	6.3		40.5	15.1		12.1	6.3		38.3	15.1	
<b>PAT</b>	<b>37.4</b>	<b>25.2</b>	<b>48%</b>	<b>129.8</b>	<b>64.5</b>	<b>101%</b>	<b>35.6</b>	<b>18.1</b>	<b>96%</b>	<b>112.6</b>	<b>41.4</b>	<b>172%</b>
<b>PAT Margin</b>	<b>14.9%</b>	<b>12.8%</b>	<b>220 bps</b>	<b>17.2%</b>	<b>11.3%</b>	<b>590 bps</b>	<b>15.1%</b>	<b>9.7%</b>	<b>530 bps</b>	<b>16.2%</b>	<b>7.7%</b>	<b>840 bps</b>
<b>Cash PAT<sup>^</sup></b>	<b>49.9</b>	<b>35.9</b>	<b>39%</b>	<b>165.7</b>	<b>95.6</b>	<b>73%</b>	<b>47.3</b>	<b>28.0</b>	<b>69%</b>	<b>146.1</b>	<b>70.4</b>	<b>107%</b>
<b>Cash PAT Margin</b>	<b>19.9%</b>	<b>18.1%</b>		<b>22.0%</b>	<b>16.8%</b>		<b>20.0%</b>	<b>15.0%</b>		<b>21.0%</b>	<b>13.2%</b>	

\* Other Expenses include Power & Fuel costs

<sup>^</sup> Cash PAT = PAT + Depreciation

# Balance Sheet

Particulars (Rs. Crs.)	Sept-25	Mar-25
<b>Non-Current assets</b>		
Property, Plant and Equipments	513.9	459.1
Capital Work in Process	20.9	17.4
Intangible assets	40.6	42.1
Investments	0.0	0.0
Intangible assets under development	1.6	0.3
<b>Financial Assets</b>		
Loans	0.5	0.5
Other Non-Current Assets	29.3	23.9
Income tax assets	7.1	3.8
<b>Total Non-Current Assets</b>	<b>613.9</b>	<b>547.0</b>
<b>Current Assets</b>		
Inventories	151.7	137.8
<b>Financial Assets</b>		
Trade Receivables	212.1	171.7
Cash and Cash Equivalents	25.3	23.1
Loans	0.4	0.3
Other Current Assets	51.2	52.6
Current tax assets (Net)	0.0	0.0
<b>Total Current Assets</b>	<b>440.7</b>	<b>385.6</b>
<b>Total Assets</b>	<b>1,054.6</b>	<b>932.6</b>

Particulars (Rs. Crs.)	Sept-25	Mar-25
<b>Equity</b>		
Equity Share Capital	9.2	9.2
Other Equity	626.3	538.5
<b>Total Equity</b>	<b>635.5</b>	<b>547.7</b>
<b>Non-Current Liabilities</b>		
Financial Liabilities		
Long-term borrowings	33.2	40.1
Deferred tax liabilities (net)	26.8	23.6
Other long-term liabilities	0.1	0.2
Long-term provisions	4.0	3.9
<b>Total Non-Current Liabilities</b>	<b>64.1</b>	<b>67.8</b>
<b>Current Liabilities</b>		
Short-term borrowings	155.9	147.6
Trade payables	97.2	99.0
Other financial liabilities	20.9	12.5
Other current liabilities	70.8	44.0
Short-term provisions	2.4	7.1
Current tax liabilities (net)	7.9	6.9
<b>Total Current Liabilities</b>	<b>355.1</b>	<b>317.1</b>
<b>Total Equity and Liabilities</b>	<b>1,054.6</b>	<b>932.6</b>

# Balance Sheet

Particulars (Rs. Crs.)	Sept-25	Mar-25
<b>Non-Current assets</b>		
Property, Plant and Equipments	512.1	457.6
Capital Work in Process	20.9	17.4
Intangible assets	17.6	19.5
Investments	11.5	11.3
Intangible assets under development	1.6	0.3
<b>Financial Assets</b>		
Loans	0.5	0.5
Other Non-Current Assets	29.3	23.9
Income tax assets	1.3	1.5
<b>Total Non-Current Assets</b>	<b>594.9</b>	<b>532.0</b>
<b>Current Assets</b>		
Inventories	151.7	137.8
<b>Financial Assets</b>		
Trade Receivables	172.5	148.1
Cash and Cash Equivalents	5.1	8.5
Loans	0.4	0.3
Other Current Assets	46.4	44.0
Current tax assets (Net)	0.0	0.0
<b>Total Current Assets</b>	<b>376.1</b>	<b>338.7</b>
<b>Total Assets</b>	<b>971.0</b>	<b>870.6</b>

Particulars (Rs. Crs.)	Sept-25	Mar-25
<b>Equity</b>		
Equity Share Capital	9.2	9.2
Other Equity	555.4	487.0
<b>Total Equity</b>	<b>564.6</b>	<b>496.2</b>
<b>Non-Current Liabilities</b>		
Financial Liabilities		
Long-term borrowings	33.2	40.1
Deferred tax liabilities (net)	24.5	22.6
Other long-term liabilities	0.1	0.2
Long-term provisions	4.0	3.9
<b>Total Non-Current Liabilities</b>	<b>61.8</b>	<b>66.8</b>
<b>Current Liabilities</b>		
Short-term borrowings	155.9	147.6
Trade payables	91.9	97.9
Other financial liabilities	20.9	12.5
Other current liabilities	70.6	38.0
Short-term provisions	2.4	7.1
Current tax liabilities (net)	2.9	4.4
<b>Total Current Liabilities</b>	<b>344.6</b>	<b>307.6</b>
<b>Total Equity and Liabilities</b>	<b>971.0</b>	<b>870.6</b>

# Cash Flow Statement

Particulars (Rs. Cr.)	Consolidated		Standalone	
	H1 FY26	H1 FY25	H1 FY26	H1 FY25
<b>Profit Before Tax</b>	120.8	48.2	103.1	32.1
Adjustments	31.4	28.4	24.3	23.8
<b>Operating profit before working capital changes</b>	<b>152.1</b>	<b>76.6</b>	<b>127.5</b>	<b>55.9</b>
Changes in working capital	-24.9	-6.7	-11.0	9.5
<b>Cash generated from operations</b>	<b>127.3</b>	<b>69.9</b>	<b>116.4</b>	<b>65.4</b>
Direct taxes paid (net of refund)	-28.8	-3.6	-25.6	-3.6
<b>Net Cash from Operating Activities</b>	<b>98.4</b>	<b>66.3</b>	<b>90.9</b>	<b>61.8</b>
<b>Net Cash from Investing Activities</b>	<b>-89.6</b>	<b>-32.2</b>	<b>-87.5</b>	<b>-19.2</b>
<b>Net Cash from Financing Activities</b>	<b>-6.7</b>	<b>-45.9</b>	<b>-6.7</b>	<b>-45.9</b>
<b>Net Change in cash and cash equivalents</b>	<b>2.2</b>	<b>-11.8</b>	<b>-3.4</b>	<b>-3.3</b>
Add: Cash & Cash equivalents at the beginning of the period	19.1	22.2	4.4	4.4
<b>Closing Cash Balance</b>	<b>21.2</b>	<b>10.4</b>	<b>1.0</b>	<b>1.2</b>

## Enriching Lives Through Plastics



Founded  
in 1987

**Shaily Engineering Plastics Limited** is India's largest exporter of plastics components. Established in 1987, the Company provides end-to-end solutions in plastic products and services, whilst delivering superior quality and value to all stakeholders.

The Company employs over 2,000+ employees and have over 200+ injection molding machines, with precise, high speed automated and robotic production lines.

Revenue\*  
**Rs. 787 Crores**  
FY 25

**200+**  
Injection moulding  
machines


**7 Facilities in  
Gujarat**  
6 for Plastic  
1 for Steel Furniture

Over  
**2,000** employees  
across 7 plants

**Long-standing  
global relationships  
with marquee clients**


**De-risked  
Business Model**






## Consumer

- ✓ Home Furnishings
- ✓ FMCG Packaging
- ✓ LED Lights
- ✓ Toys
- ✓ Carbon Steel Furniture



## Industrial

- ✓ Automotive Components
- ✓ Appliances
- ✓ High Performance Engineering Components




## Healthcare

- ✓ Platform Devices
- ✓ Drug Delivery Devices
- ✓ Pharma Packaging



**7 Facilities with over 200 molding machines ranging from 35 tons to 1,000 tons**



## Rania

- ❖ Export Oriented Unit
- ❖ Pharma (Dedicated ISO Class 8 clean room manufacturing facility)
- ❖ Others

## Halol (GIDC)

- ❖ Automotive & Engineering

## Halol

- ❖ Carbon Steel
- ❖ Plastic

# Board of Directors



**Executive Chairman**

**Mr. Mahendra Sanghvi**

**Whole Time Director**

**Ms. Tilottama Sanghvi**

**Managing Director**

**Mr. Amit Sanghvi**

**Executive Director**

**Mr. Laxman Sanghvi**

**Independent Director**

**Dr. Shailesh Ayyangar**

**Independent Director**

**Mr. Ranjit Singh**

**Independent Director**

**Mr. Samaresh Parida**

**Independent Director**

**Mrs. Sangeeta Singh**

## LONG TERM BANK FACILITIES

Rs. 239.62 Crs.

**CARE A+ ; Outlook: Stable**

Rating Action: Reaffirmed

## SHORT TERM BANK FACILITIES

Rs. 35 Crs.

**CARE A1**

Rating Action: Reaffirmed



Long and established track record in the plastic injection molding business along with experienced Promoters



Growth in Total operating income on the back of increased volumes & higher exports



Sustainable healthy operating margin along with strengthening leverage and debt coverage indicators



New business confirmations from existing clients along with addition of marquee clients across diversified industries



Sustainable healthy operating margin along with strengthening leverage and debt coverage indicators

# Historical Profit & Loss Statement



Consolidated				Standalone		
Particulars (Rs. Crs.)	FY25	FY24	FY23	FY25	FY24	FY23
<b>Revenue</b>	<b>786.8</b>	<b>643.9</b>	<b>607.1</b>	<b>738.1</b>	<b>616.0</b>	<b>599.7</b>
Raw Material	415.8	370.1	386.5	415.7	370.1	386.5
Employee Expenses	80.4	57.3	47.9	72.8	55.9	47.2
Other Expenses*	114.5	99.5	80.8	106.0	95.2	79.4
Other Income	2.3	6.5	4.5	7.4	6.5	4.5
<b>EBITDA</b>	<b>178.4</b>	<b>123.4</b>	<b>96.4</b>	<b>151.0</b>	<b>101.3</b>	<b>91.1</b>
<b>EBITDA Margin</b>	<b>22.7%</b>	<b>19.2%</b>	<b>15.9%</b>	<b>20.5%</b>	<b>16.4%</b>	<b>15.2%</b>
Depreciation	42.2	35.7	33.3	39.4	34.7	33.2
Finance Cost	16.9	17.9	17.9	16.9	17.9	17.9
<b>PBT</b>	<b>119.3</b>	<b>69.8</b>	<b>45.2</b>	<b>94.7</b>	<b>48.7</b>	<b>40.1</b>
<b>PBT Margin</b>	<b>15.2%</b>	<b>10.8%</b>	<b>7.4%</b>	<b>12.8%</b>	<b>7.9%</b>	<b>6.7%</b>
Tax	26.2	12.6	10.1	23.7	12.6	10.1
<b>PAT</b>	<b>93.1</b>	<b>57.3</b>	<b>35.1</b>	<b>70.9</b>	<b>36.1</b>	<b>30.0</b>
<b>PAT Margin</b>	<b>11.8%</b>	<b>8.9%</b>	<b>5.8%</b>	<b>9.6%</b>	<b>5.9%</b>	<b>5.0%</b>
<b>Cash PAT<sup>▲</sup></b>	<b>135.3</b>	<b>93.0</b>	<b>68.5</b>	<b>110.3</b>	<b>70.8</b>	<b>63.2</b>
<b>Cash PAT Margin</b>	<b>17.2%</b>	<b>14.4%</b>	<b>11.3%</b>	<b>14.9%</b>	<b>11.5%</b>	<b>10.5%</b>

# Historical Balance Sheet

Particulars (Rs. Crs.)	Mar-25	Mar-24	Mar-23
<b>Non-Current assets</b>			
Property, Plant and Equipments	459.1	435.4	347.9
Capital Work in Process	17.4	15.3	49.0
Intangible assets	42.1	38.0	19.0
Investments	-	0.0	0.0
Intangible assets under development	0.3	5.1	19.3
<b>Financial Assets</b>			
Loans	0.5	0.5	0.5
Other Non-Current Assets	23.9	18.3	17.2
Income tax assets	3.8	2.7	2.1
<b>Total Non-Current Assets</b>	<b>547.0</b>	<b>515.3</b>	<b>455.0</b>
<b>Current Assets</b>			
Inventories	137.8	83.6	73.0
<b>Financial Assets</b>			
Trade Receivables	171.7	117.4	91.9
Cash and Cash Equivalents	23.1	26.4	23.0
Loans	0.3	6.4	5.7
Other Current Assets	52.6	33.5	44.1
Current tax assets (Net)	-	0.0	0.0
<b>Total Current Assets</b>	<b>385.6</b>	<b>267.2</b>	<b>237.7</b>
<b>Total Assets</b>	<b>932.6</b>	<b>782.5</b>	<b>692.7</b>

Particulars (Rs. Crs.)	Mar-25	Mar-24	Mar-23
<b>Equity</b>			
Equity Share Capital	9.2	9.2	9.2
Other Equity	538.5	450.0	392.2
<b>Total Equity</b>	<b>547.7</b>	<b>459.2</b>	<b>401.4</b>
<b>Non-Current Liabilities</b>			
Financial Liabilities			
Long-term borrowings	40.1	69.8	62.5
Deferred tax liabilities (net)	23.6	20.8	17.0
Other long-term liabilities	0.2	1.2	1.2
Long-term provisions	3.9	2.2	2.3
<b>Total Non-Current Liabilities</b>	<b>67.8</b>	<b>94.1</b>	<b>83.1</b>
<b>Current Liabilities</b>			
Short-term borrowings	147.6	138.5	124.3
Trade payables	99.0	68.7	53.4
Other financial liabilities	12.5	10.3	9.3
Other current liabilities	44.0	10.4	20.0
Short-term provisions	7.1	1.3	1.2
Current tax liabilities (net)	6.9	0.0	0.0
<b>Total Current Liabilities</b>	<b>317.1</b>	<b>229.2</b>	<b>208.2</b>
<b>Total Equity and Liabilities</b>	<b>932.6</b>	<b>782.5</b>	<b>692.7</b>

# Historical Balance Sheet

Particulars (Rs. Crs.)	Mar-25	Mar-24	Mar-23
<b>Non-Current assets</b>			
Property, Plant and Equipments	457.6	434.9	348.6
Capital Work in Process	17.4	15.3	49.0
Intangible assets	19.5	17.8	13.8
Investments	11.3	20.6	15.4
Intangible assets under development	0.3	2.1	5.7
<b>Financial Assets</b>			
Loans	0.5	0.5	0.5
Other Non-Current Assets	23.9	18.3	17.2
Income tax assets	1.5	2.3	2.1
<b>Total Non-Current Assets</b>	<b>532.0</b>	<b>511.8</b>	<b>452.3</b>
<b>Current Assets</b>			
Inventories	137.8	83.6	73.0
<b>Financial Assets</b>			
Trade Receivables	148.1	111.7	88.8
Cash and Cash Equivalents	8.5	8.6	17.7
Loans	0.3	6.4	13.7
Other Current Assets	44.0	29.9	39.2
Current tax assets (Net)	-	0.0	0.0
<b>Total Current Assets</b>	<b>338.7</b>	<b>240.3</b>	<b>232.4</b>
<b>Total Assets</b>	<b>870.6</b>	<b>752.1</b>	<b>684.6</b>

Particulars (Rs. Crs.)	Mar-25	Mar-24	Mar-23
<b>Equity</b>			
Equity Share Capital	9.2	9.2	9.2
Other Equity	487.0	422.3	386.5
<b>Total Equity</b>	<b>496.2</b>	<b>431.5</b>	<b>395.6</b>
<b>Non-Current Liabilities</b>			
Financial Liabilities			
Long-term borrowings	40.1	69.8	62.5
Deferred tax liabilities (net)	22.6	20.4	16.9
Other long-term liabilities	0.2	1.2	1.2
Long-term provisions	3.9	2.2	2.3
<b>Total Non-Current Liabilities</b>	<b>66.8</b>	<b>93.6</b>	<b>82.9</b>
<b>Current Liabilities</b>			
Short-term borrowings	147.6	138.5	123.2
Trade payables	97.9	67.2	51.7
Other financial liabilities	12.5	10.3	10.4
Other current liabilities	38.0	9.7	19.5
Short-term provisions	7.1	1.3	1.2
Current tax liabilities (net)	4.4	0.0	0.0
<b>Total Current Liabilities</b>	<b>307.6</b>	<b>227.0</b>	<b>206.1</b>
<b>Total Equity and Liabilities</b>	<b>870.6</b>	<b>752.1</b>	<b>684.6</b>

# Cash Flow Statement

Particulars (Rs. Crs.)	Consolidated			Standalone		
	FY25	FY24	FY23	FY25	FY24	FY23
<b>Profit Before Tax</b>	119.3	69.8	45.2	94.7	48.7	40.1
Adjustments	56.6	58.2	51.4	46.6	56.2	50.4
<b>Operating profit before working capital changes</b>	<b>175.9</b>	<b>128.0</b>	<b>96.6</b>	<b>141.3</b>	<b>104.8</b>	<b>90.5</b>
Changes in working capital	-48.3	-27.0	-0.6	-30.5	-21.6	0.2
<b>Cash generated from operations</b>	<b>127.6</b>	<b>101.0</b>	<b>96.0</b>	<b>110.7</b>	<b>83.3</b>	<b>90.7</b>
Direct taxes paid (net of refund)	-17.5	-8.8	-6.0	-15.1	-8.8	-6.0
<b>Net Cash from Operating Activities</b>	<b>110.1</b>	<b>92.3</b>	<b>90.0</b>	<b>95.6</b>	<b>74.5</b>	<b>84.7</b>
<b>Net Cash from Investing Activities</b>	<b>-71.3</b>	<b>-99.0</b>	<b>-100.9</b>	<b>-53.7</b>	<b>-92.4</b>	<b>-93.3</b>
<b>Net Cash from Financing Activities</b>	<b>-41.9</b>	<b>9.8</b>	<b>-5.1</b>	<b>-41.9</b>	<b>4.6</b>	<b>-5.1</b>
<b>Net Change in cash and cash equivalents</b>	<b>-3.1</b>	<b>3.1</b>	<b>-16.0</b>	<b>0.0</b>	<b>-13.3</b>	<b>-13.7</b>
Add: Cash & Cash equivalents at the beginning of the period	22.2	19.1	35.1	4.4	17.7	31.4
<b>Closing Cash Balance</b>	<b>19.1</b>	<b>22.2</b>	<b>19.1</b>	<b>4.4</b>	<b>4.4</b>	<b>17.7</b>

**Company :**

**Shaily Engineering Plastics Ltd.**  
CIN – L51900GJ1980PLC065554

Mr. Sanjay Shah, Chief Strategy Officer  
[sanjay@shaily.com](mailto:sanjay@shaily.com)  
[www.shaily.com](http://www.shaily.com)

**SGA** Strategic Growth Advisors**Investor Relations Advisors :**

**Strategic Growth Advisors Pvt. Ltd.**  
CIN - U74140MH2010PTC204285

Mr. Shogun Jain / Mr. Deven Dhruva  
[shogun.jain@sgapl.net](mailto:shogun.jain@sgapl.net) / [deven.dhruva@sgapl.net](mailto:deven.dhruva@sgapl.net)  
+91 77383 77756 / +91 98333 73300  
[www.sgapl.net](http://www.sgapl.net)

